| 货号 | AF6196-SP |
| 别名 | CRP2; CRP2LIM domain only protein 5; cysteine and glycine-rich protein 2; Cysteine-rich protein 2; LMO5LMO-5; SmLIM; SmLIMLIM domain only 5, smooth muscle; Smooth muscle cell LIM protein | 全称 | Cysteine-rich Protein 2 |
| 反应种属 | Human |
| 应用 | Western Blot(2 µg/mL) |
| 目标/特异性 | Detects human CSRP2 in Western blots. |
| 使用方法 | Western Blot: 2 µg/mL |
| 来源 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 1466 (Human); 13008 (Mouse); 29317 (Rat) |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | E. coli-derived recombinant human CSRP2 Met1-Gln193 Accession # Q16527 |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | CSRP2 (Cysteine‑rich protein 2/CRP2; also Cysteine and Glycine‑rich protein 2, LMO‑5 and SmLIM) is a 21‑22 kDa member of the CRP family of LIM domain‑containing proteins. It is expressed in arterial smooth muscle, hepatic stellate cells and fibroblasts. CSRP2 is up‑regulated by TGF‑ beta and down‑regulated by PDGF, and appears to interact with PIAS1 and CRP2‑BP, thus promoting STAT signaling. It also binds to SRF and GATA4 to initiate smooth muscle differentiation. Human CSRP2 is 193 amino acids (aa) in length and contains two 50 aa LIM (for lin11/isl1/mec3) domains that contain two zinc‑finger motifs (aa 10‑61 and 119‑170), an NLS between aa 64‑69, and a Gly‑rich C‑terminus (aa 176‑187). Full‑length human CSRP2 shares 79% aa identity with human CSRP1. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
Detection of Human CSRP2 by Western Blot. Western blot shows lysates of ME‑180 human cervical epithelial carcinoma cell line and HeLa human cervical epithelial carcinoma cell line. PVDF Membrane was probed with 2 µg/mL of Goat Anti-Human CSRP2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6196) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). A specific band was detected for CSRP2 at approximately 21 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1. |
